Article Text

Download PDFPDF
Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits
  1. Elodie Rivière1,2,
  2. Bineta Ly2,
  3. Saida Boudaoud2,
  4. Houria Chavez2,
  5. Gaetane Nocturne1,2,
  6. Philippe Chanson3,
  7. Corinne Miceli Richard1,2,
  8. Xavier Mariette1,2
  1. 1 Rheumatology Department, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France
  2. 2 INSERM U1184, Université Paris-Sud, Le Kremlin-Bicêtre, France
  3. 3 Endocrinology Department, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France
  1. Correspondence to Professor Xavier Mariette, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94270, France; xavier.mariette{at}

Statistics from

The recent interest for interleukin-33 (IL-33) in primary Sjögren syndrome (pSS) pathophysiology is due to three studies,1–3 which have shown an increase in IL-33 serum levels in patients with pSS compared with controls. IL-33 is a member of the IL-1 family which is released in case of cellular damage and acts as an alarmin; however, its role in pSS physiopathology remains unclear.

In the present study, we aimed to replicate the association described between IL-33 serum level and pSS diagnosis. For that purpose, we used Quantikine and Duoset ELISA (R&D Systems, Minnesota, USA) and Luminex (Milliplex HTh17, Merck, Darmstadt, Germany). The Quantikine and Luminex kits are validated for serum samples, while the Duoset is only validated for use with culture supernates (data from R&D). IL-33 serum levels were assessed in patients with pSS from the French multicentre prospective ASSESS cohort (Assessment of Systemic Signs and Evolution in Sjögren Syndrome, principal investigator: X …

View Full Text


  • Contributors ER designed and performed experiments, analysed data and wrote the manuscript. BL performed experiments and analysed data. SB, GN and CMR designed experiments and analysed data. PC provided serum samples for Variété controls. XM designed experiments, analysed data and revised the manuscript.

  • Funding We thank the French Society of Rheumatology which provided financial support.

  • Competing interests None declared.

  • Ethics approval Local Ethic Committee of Hôpital Bichat and the ‘Comission Nationale informatique et Liberté’ in 2006.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement All the authors in this current work declare that there are no unpublished data and that all data have been presented in the current manuscript.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.